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1552Comparison of Allogeneic Stem Cell Transplantation
from Familial-Mismatched/Haploidentical Donors and
from Unrelated Donors in Adults with High-Risk Acute
Myelogenous Leukemia
Byung-Sik Cho, Jae-Ho Yoon, Seung-Hwan Shin, Seung-Ah Yahng, Sung-Eun Lee,
Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim,
Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Hee-Je KimTo weigh the pros and cons of familial-mismatched/haploidentical transplantation (FMT) in patients with
high-risk acute myelogenous leukemia, we assessed outcomes of 23 patients who underwent FMT, using
reduced-intensity conditioning with total body irradiation 800 cGy/busulfan/fludarabine/antithymocyte glob-
ulin without ex vivo T cell depletion, compared to 33 patients who underwent well-matched unrelated donor
transplantation (WM-UDT) and 13 who underwent partially matched unrelated donor transplantation (PM-
UDT) during the same period. The FMT patients had not only a similar pattern of engraftment and immune
reconstitution as the WM-UDTand PM-UDT patients but also comparable incidences and severity of acute
and chronic graft-versus-host disease. The FMT patients did not experience any form of engraftment failure.
However, the cumulative incidence of cytomegalovirus DNAemia was significantly higher in the FMT group
compared with the other groups (P5.036). After a median follow-up of 28 months, overall survival, disease-
free survival, relapse, and nonrelapse mortality were 83%, 74%, 20%, and 7%, respectively, for WM-UDT;
51%, 51%, 31%, and 18% for PM-UDT; and 66%, 64%, 26%, and 10% for FMT. This demonstrates a trend
for favorable survival outcomes of WM-UDTover FMT and of FMTover PM-UDT. However, we found no
significant statistical differences in survival according to donor type. These data need to be interpreted cau-
tiously because of limited power calculations due to the small number of each donor group. This pilot study
suggests the feasibility of FMTusing our novel regimen with careful evaluation of CMV DNAemia compared
with WM-UDT and PM-UDT. Further trials with larger numbers of patients, comparing FMT directly with
transplantation with other donor types, are needed.
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(CR1). Recent meta-analyses of prospective clinical
trials have shown that allogeneic SCT has a significant
overall survival (OS) benefit for intermediate- and
high-risk AML in CR1 compared with nonallogeneic
SCT therapies [1-3]. Patients who achieve late CR1
or those with advanced disease may also be treated
by allogeneic SCT [4]; however, only 30% of patients
with indications for allogeneic SCTwill have anHLA-
identical sibling [5,6]. For patients lacking an HLA-
identical sibling, a well-matched unrelated donor
(WM-UD) is currently the gold standard donor [6],
since outcomes after HLA-identical sibling SCT
have been demonstrated to be comparable with those
after WM-UD SCT [7].
Currently, there are 3 available alternative graft
sources: mismatched unrelated donors, familial mis-
matched/haploidentical donors (FMD), and umbilical
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-B, -C, and -DRB1 is considered the minimum for
matching associated with the highest survival, whereas
single ormultiplemismatches are associatedwith lower
survival and higher mortality [8,9]. Each additional
mismatch is associated with an increased risk of
complications and an approximate 11% decrease in
5-year OS [10]. An adult donor is considered accept-
able if matched at a minimum of 7 of 8 HLA alleles
from HLA-A, -B, -C, and -DR loci; this is referred to
as a partially matched unrelated donor (PM-UD) [9,11].
Compared with other sources, transplantations
with FMD (FMT) have the benefit of immediate do-
nor availability, which is particularly important for
those patients requiring urgent transplantation [5,6].
Initial reports had associated FMT with poor
engraftment and a high incidence of graft-versus-
host disease (GVHD) [12,13]; however, outcomes of
FMT have improved significantly over the past
decade with the optimization of conditioning
regimens and graft selection to allow a stable
engraftment across major HLA barriers, producing
promising leukemia-free survival in adults with acute
leukemia [14-18]. Furthermore, FMT, as well as
transplantation from mismatched unrelated donors,
may harness the potential of natural killer (NK) cell
alloreactivity to kill tumor cells and reduce the risk
of posttransplantation relapse, particularly in patients
with AML, although data are conflicting on this [19].
Despite the encouraging results and potential ben-
efit of FMT, few published studies have compared
clinical outcomes of FMT with transplantation with
other donor types, particularly in AML as a single dis-
ease. Since August 2008, we have been continuously
performing FMT using unmanipulated donor cells
and a less-aggressive conditioning regimen in patients
with high-risk AML lacking an HLA-identical sibling,
those with a WM-UD, and those with a PM-UD [20].
To weigh the pros and cons of FMT, we evaluated the
clinical outcomes of FMT in patients with high-risk
AML compared with transplantations with WM-UD
(WM-UDT) and PM-UD (PM-UDT) during the
same period.PATIENTS AND METHODS
Patient Characteristics
Sixty-nine consecutive adult patients with high-
risk AML underwent allogeneic SCT from unrelated
donors (WM-UD and PM-UD) or FMD at the Cath-
olic Blood and Marrow Transplantation Center of
Korea between August 2008 and December 2010.
The patients included those with AML in CR1
(n5 52), with intermediate or high-risk chromosomal
or molecular features based on the 2011 guidelines of
the National Comprehensive Cancer Network [21],and those with advanced disease status at transplanta-
tion (CR2, CR3, or refractory; n 5 17). We screened
all patients and donors for HLA-A, -B, -C, and
-DRB1 alleles using a high-resolution (DNA sequenc-
ing) molecular typing method. In the absence of an
HLA-matched sibling donor, based on our method
of locating unrelated donors as described previously
[22], 46 patients underwent SCT with a WM-UD
(n5 33) or a PM-UD (n5 13), and 23 patients under-
went SCT with an FMD in the absence of an HLA-
matched sibling, a WM-UD, or a PM-UD. Table 1
presents demographic data for all patients. The study
group comprised 46 males and 23 females (median
age, 40 years; range, 16-70 years) with de novo AML
(n 5 59; 86%) or AML with myelodysplasia-related
changes (n 5 10; 14%). The majority of patients
(n 5 66; 95%) had intermediate (n 5 52; 75%) or un-
favorable (n 5 14; 20%) cytogenetic and molecular
features based on the 2011 National Comprehensive
Cancer Network criteria guidelines [21]. The 3 pa-
tients with favorable cytogenetics were in CR2
(n 5 2) or had persistent disease (n 5 1) at transplan-
tation. All but 1 patient (99%) and 49 donors (71%)
were cytomegalovirus (CMV)-seropositive.Transplantation Procedure
The patients undergoing WM-UDT and PM-
UDT received a myeloablative conditioning (MAC)
regimen (n 5 32; 70%) or a reduced-intensity condi-
tioning (RIC) regimen (n5 14; 30%). MAC regimens
included total body irradiation (TBI; 1320 cGy;
n 5 19) or busulfan (3.2 mg/kg/day i.v. in 4 divided
doses for 4 days; n 5 13) with cyclophosphamide (60
mg/kg/day i.v. for 2 days). Older patients (.55 years)
and/or patients with comorbidities received an RIC
regimen with fludarabine (30 mg/m2/day i.v. on days
26 to 22), busulfan (3.2 mg/kg/day i.v. in 4 divided
doses on days 25 and 24), and TBI (400 cGy; a frac-
tion size of 200 cGy on day 21) [23]. Twenty-three
WM-UDT recipients (70%) who received peripheral
blood stem cells (PBSCs) and all PM-UDT recipients
(100%) also received antithymocyte globulin (ATG;
thymoglobulin, Genzyme, Cambridge, MA), at
a dose of 1.25 mg/kg/day on days 23 and 22 [22].
The conditioning regimen for FMT consisted of
TBI 800 cGy (a fraction size of 200 cGy on days 29
and 28), fludarabine (30 mg/m2/day i.v. on days 27
to23), busulfan (3.2 mg/kg/day i.v. in 4 divided doses
on days26 and25), and ATG (1.25 mg/kg/day i.v. on
days24 to21). PBSCs from FMDs were harvested by
large-volume leukapheresis, with the goal of collecting
at least 5  106 CD341 cells per kilogram of recipient
body weight. Granulocyte colony-stimulating factor,
10 mg/kg/day s.c., was administered from day 24 to
achievement of the cell collection goal. The collected
cells were administered without ex vivo T cell
Table 1. Patients and Transplantation Characteristics
Characteristic WM-UDT (n 5 33) PM-UDT (n 5 13) FMT (n 5 23) P Valuea
Patient age, years, median (range) 45 (17-64) 38 (20-70) 39 (16-62) .531
Donor age, years median (range) 28 (22-40) 29 (19-43) 24 (7-57) .998
Patient sex, male/female, n (%) 21 (64)/12 (36) 8 (61)/5 (39) 17 (74)/6 (26) .706
Donor sex, male/female, n (%) 26 (79)/7 (21) 6 (46)/7 (54) 12 (52)/11 (48) .046
Donor–recipient sex match, female to male/others, n (%)a 4 (12)/29 (88) 5 (39)/8 (61) 8 (35)/15 (65) .069
AML type: de novo/AML with MRC, n (%) 28 (85)/5 (15) 10 (77)/3 (23) 21 (91)/2 (9) .487
WBC at diagnosis, 109/L
Median (range) 4.45 (0.64-414.85) 20.65 (0.67-104.09) 5.6 (0.98-109.50)
<50/$50, n (%) 26 (79)/7 (21) 11 (92)/1 (8) 20 (87)/3 (13) .566
Risk groups: favorable/intermediate/adverse, n (%) 2 (6)/23 (70)/8 (24) 0 (0)/11 (85)/2 (15) 1 (4)/18 (78)/4 (18) .937
Previous SCT, n (%) .697
Yes; auto/sibling/URD 3 (9) 2 (15) 3 (13)
No 30 (91) 11 (85) 20 (87)
Pre-SCT disease status, n (%) .353
Standard, CR1 27 (82) 8 (61) 17 (74)
Advanced; CR2/CR3/reference 6 (18) 5 (39) 6 (26)
Time from remission to transplantation, days, median (range)b 83 (11-161) 103 (20-176) 109 (15-290) .217
ABO match/mismatch, n (%) 7 (21)/26 (79) 4 (31)/9 (69) 12 (52)/11 (48) .057
Donor/recipient CMV serostatus: +/+ / 2/+ / +/2, n (%) 23 (70) /10 (30)/0 (0) 7 (54)/6 (46)/0 (0) 18 (78)/4 (18)/1 (4) .204
Graft source: BM/PBSC, n (%) 10 (30)/23 (70) 3 (23)/10 (77) 0 (0)/23 (100) .011
Conditioning regimen: TBI-based/non–TBI-based, n (%) 22 (67)/11 (33) 11 (85)/2 (15) 23 (100)/0 (0) .003
Conditioning intensity: MAC/RIC, n (%) 23 (70)/10 (30) 9 (69)/4 (31) NA
ATG given as conditioning, yes/no, n (%) 23 (70)/10 (30) 13 (100)/0 (0) 23 (100)/0 (0) .001
MNC cells,  108/kg, median (range) 6.3 (0.5-12.8) 6.9 (0.7-11.0) 10.8 (5.7-25.9) <.001
CD34+ cells,  106/kg, median (range) 4.5 (1.4-14.2) 3.5 (0.5-10.6) 6.5 (4.7-10.5) .003
CD3+ cells,  106/kg, median (range) 282.4 (38.5-731.7) 360.3 (47.5-552.3) 542.1 (287.2-1510.5) <.001
AML with MRC indicates acute myelogenous leukemia with myelodysplasia-related changes; BM, bone marrow; MNC, mononuclear cells.
aValues for categorical variables were analyzed using the c2 or Fisher exact test to compare the characteristics of three donor types. One-way ANOVA
were used to compare the continuous variables.
bOnly patients with remission state at transplantation (n 5 64) were included.
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same day as collection.
GVHD Prophylaxis and Management
For GVHD prophylaxis, all patients received
a combination of tacrolimus and short-course metho-
trexate (MTX). Tacrolimus was administered i.v. as
a continuous infusion at a dosage of 0.03 mg/kg from
days 21, to 121, then orally at a total dose of 0.12
mg/kg/day divided into 2 doses to maintain a blood
concentration between 10 and 20 ng/mL [24]. MTX
was administered at a dosage of 5 mg/m2 on days
11, 13, 16 and 111. In the absence of acute
GVHD (aGVHD), tacrolimus was tapered by 25% bi-
weekly, beginning on day 90 after SCT. The primary
treatment for aGVHD consisted mainly of methyl-
prednisolone (2 mg/kg) or an equivalent dose of pred-
nisone. The treatment of steroid-refractory aGVHD
was variable, as described previously [25]. The treat-
ment of chronic GVHD (cGVHD) was also variable;
in accordance with National Institutes of Health rec-
ommendations [26], the mild type was treated with
topical immunosuppressants, whereas both moderate
and severe types were treated with a calcineurin inhib-
itor and systemic steroids.
Supportive Care
Granulocyte colony-stimulating factor was admin-
istered s.c. to all patients at a dose of 5 mg/kg/day fromday 7 posttransplantation until neutrophil recovery.
Low-dose heparin (Hanlim, Seoul, Korea; 100 U/kg/
day continuous i.v. infusion) or lipo-prostaglandin
E1 (Eglandin; alprostadil, Welfide, Osaka, Japan; 1
mg/kg/day continuous i.v. infusion) was administered
with ursodiol (200mg 3 times a day) for the prevention
of veno-occlusive disease. All patients received selec-
tive gut decontamination with ciprofloxacin (500 mg
twice a day) and itraconazole oral solution (200 mg
twice a day) or i.v. micafungin (50 mg daily) from the
start of conditioning until engraftment. High-dose
i.v. acyclovir (10 mg/kg 3 times a day) was adminis-
tered from the the start of conditioning until engraft-
ment for WM-UDT and PM-UDT, whereas i.v.
ganciclovir (5 mg/kg twice a day) instead of high-
dose acyclovir during the conditioning period was
administered for FMT, to reinforce the CMV prophy-
laxis. From the time of neutrophil engraftment to hos-
pital discharge, patients were monitored for CMV
infection twice a week with a real-time polymerase
chain reaction (PCR)-based assay for CMV DNA us-
ing a LightCycler 2.0 instrument (Roche Diagnostics,
Mannheim, Germany). CMV DNA load-guided, risk-
adapted preemptive therapy with ganciclovir (5 mg/kg
twice a day) or foscarnet (60 mg/kg 3 times a day or 90
mg/kg twice a day) was conducted with the objective of
preventingCMVdisease [27]. Patients were thenmon-
itored weekly to biweekly until the cessation of the
immunosuppressive drugs. Every patient received
Pneumocystis jirovecci prophylaxis with trimethoprim/
Biol Blood Marrow Transplant 18:1552-1563, 2012 1555Familial-Mismatched Versus Unrelated Transplantsulfamethoxazole (one single-strength tablet daily)
after engraftment until discontinuation of the immu-
nosuppressant therapy. On day 28 posttransplantation,
chimerism of donor and recipient cells in the periph-
eral blood for 16 human-specific gene probes was
assessed by multiplex fluorescent short tandem repeat
analysis (multiplex and automated fragment analyzer-
based typing; Applied Biosystems, Foster City, CA).
Posttransplantation immune reconstitution was
estimated by counting CD41 lymphocytes, CD81
lymphocytes, CD191 lymphocytes, and CD561 cells
in peripheral blood at 1, 3, 6, 9, and 12 months after
SCT.
Definitions
Neutrophil engraftment was defined as an absolute
neutrophil count of.0.5  109/L during the first of 3
consecutive days. Platelet engraftment was defined as
a platelet count of .20  109/L without transfusion
support during the first of 7 consecutive days. Primary
graft failure was defined as failure to achieve a neutro-
phil count of .0.5  109/L for 3 consecutive days at
any time after SCT. Secondary graft failure was de-
fined as the development of an absolute neutrophil
count of\0.5  109/L after achievement of initial en-
graftment. Hepatic veno-occlusive disease, aGVHD,
cGVHD, CMVDNAemia, and CMV disease were di-
agnosed and graded using previously published criteria
[26,28-30].
Statistical Analyses
The primary aim of this study was to evaluate the
differences in clinical outcomes according to donor
type (WM-UD versus PM-UD versus FMD). Major
study endpoints included OS, disease-free survival
(DFS), and cumulative incidences of relapse or nonre-
lapse mortality (NRM). Secondary endpoints were cu-
mulative incidences of main complications, such as
aGVHD, cGVHD, and CMV DNAemia. OS and
DFS curves were plotted using the Kaplan-Meier
method and compared by the log-rank test. The cumu-
lative incidence was used to estimate the probability of
relapse, NRM, and each subtype of GVHD, treating
nonrelapse death, relapse, and non-GVHD death as
competing risks for relapse, NRM, and each subtype
of GVHD, respectively, and compared using the
Gray test [31]. CMVDNAemia was also calculated us-
ing cumulative incidence estimates. Values for cate-
gorical variables were analyzed using the c2 test or
Fisher exact test to compare the characteristics of 3
groups of donors. One-way analysis of variance was
used to compare the continuous variables. For multi-
variate analysis, variables with a P value\.10, as deter-
mined by univariate analysis, were considered for entry
into the model selection procedure on the basis of the
Cox proportional hazards model. The prognostic sig-nificances of presenting and transplantation-related
covariates affecting OS and DFS were determined us-
ing the Cox proportional hazard model. Factors were
considered significant if they had an associated P value
of\.05 as determined by the likelihood ratio test using
2-tailed significance testing. In contrast, the prognos-
tic significance of covariates affecting NRM, relapse,
aGVHD, cGVHD, and CMV DNAemia was deter-
mined using a proportional hazardsmodel for a subdis-
tribution of competing risks [31]. Statistical analyses
were performed using SPSS 13.0 (SPSS, Chicago,
IL), except for the cumulative incidence analyses,
which were carried out with R functions from
competing-risks analysis libraries (R version 2.9.1;
R Foundation for Statistical Computing, Vienna,
Austria).RESULTS
Patient and Donor Characteristics
Table 1 presents patient demographic data accord-
ing to donor type. Patients and disease characteristics,
including age of patients and donors, sex of patients,
AML type, WBC count at diagnosis, risk groups, pre-
vious SCT, pre-SCT disease status, time from remis-
sion to SCT, ABO match, and donor–recipient
CMV serostatus, were similar in the 3 donor groups,
with the exception of a higher proportion of male do-
nors in WM-UDT. On the other hand, there were
some differences in transplantation-related character-
istics, including conditioning regimens, sources of
graft, proportion of ATG given as conditioning, and
infused cell numbers, related to differences in FMT
strategies, as noted earlier. The FMT group had
a higher proportion of TBI- or ATG-containing con-
ditioning and the usage of PBSCs compared with the
other 2 groups. In particular, the numbers of infused
CD341 and CD31 cells were significantly higher in
the FMT group.
Table 2 presents the characteristics of the HLA-
mismatched donors in the PM-UDT and FMT
groups. Donors in the PM-UDT group included 9
class I HLA mismatches and 4 HLA-DRB1 mis-
matches. The 23 donors of FMT were patients’ off-
spring (n 5 12), mothers (n 5 7), or siblings (n 5 4).
Between donors and patients, there were a mean of
2.74 mismatches of the 8 HLA-A, -B, -C, and -DR an-
tigens in the graft-versus-host direction and a mean of
2.30 mismatches of these 8 antigens in the rejection di-
rection, whereas by allele level, there were a mean of
2.96 mismatches in the graft-versus-host direction
and 3.17 mismatches in the rejection direction.
When classified according to killer immunoglobulin-
like receptor ligand incompatibility [19], 61% of the
FMT group and 23% of the PM-UDT group ex-
hibited donor NK cell alloreactivity (P 5 .041).
Table 2. Characteristics of Mismatched Transplantations
According to Donor Type
Characteristic
PM-UDT
(n 5 13)
FMT
(n 5 23)
Donor
Unrelated 13 —
Offspring — 12
Mother — 7
Sibling — 4
Location of HLA mismatch
Only 1 allele at HLA-A 3 —
Only 1 allele at HLA-B 3 —
Only 1 allele at HLA-DRB1 4 —
Only 1 antigen at HLA-C 3 —
1 antigen at HLA-A and 1 allele at
HLA-DRB1
— 1
Antigens at HLA-A, -DRB1 — 2
Antigens at HLA-C, -DRB1 — 1
Antigens at HLA-A, -B, -C — 3
Antigens at HLA-A, -B, -DRB1 — 2
Antigens at HLA-B, -C, -DRB1 — 4
Antigens at HLA-A, -B, -C, -DRB1 — 10
Number of HLA mismatches
By antigen
GVH direction, 0/1/2/3/4 — 1/2/5/8/7
HVG direction, 0/1/2/3/4 — 1/1/4/8/9
By allele
GVH direction, 0/1/2/3/4 — 1/1/6/5/10
HVG direction, 0/1/2/3/4 — 1/0/4 /7/11
Donor–recipient NK cell
alloreactivity, yes/no
3 (23%)/10 (77%) 14 (61%)/9 (39%)
GVH indicates graft-versus-host; HVG, host-versus-graft.
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Recovery
All patients achieved initial donor cell engraft-
ment. The median time for neutrophils to reach a level
of 0.5  109/L for 3 consecutive days was 12 days
(range, 10-21 days) in the WM-UDT group, 12 days
(range, 9-22 days) in the PM-UDT group, and 11
days (range, 10-17 days) in the FMT group. The me-
dian time for the platelet count to increase to
.20  109/L without platelet transfusion was 13
days (range, 8-60) in the WM-UDT group, 13 days
(range, 9-25 days) in the PM-UDT group, and 12
days (range, 8-40 days) in the FMT group. ThereFigure 1. Engraftment according to donor type. (A) Nwas no significant difference in either neutrophil
(P5 .254) and platelet (P 5 .259) engraftment among
the donor groups (Figure 1). No recipient in any group
experienced secondary engraftment failure.
Assessment of posttransplantation hematopoietic
chimerism with peripheral blood mononuclear cells
at 4 weeks after SCT revealed that all but 4 patients
achieved .90% donor chimerism. In the 4 patients
who did not, the short tandem repeat values were
88.7% (FMT), 84.2% (WM-UDT), 63.5% (WM-
UDT), and 64.3% (PM-UDT). Three of these 4 pa-
tients achieved full-donor chimerism and survived;
the remaining patient, a PM-UDT recipient, experi-
enced early relapse and died within 100 days post-
SCT.
Among the patients who survived at least 6 months
without relapse between 1 month and 12 months post-
SCT, posttransplantation-immune reconstitution was
analyzed in 15 of 31 patients in the WM-UDT group
and in 10 of 18 patients in FMT group (Figure 2). De-
spite differences in transplantation-related character-
istics, including conditioning regimens, graft sources,
proportion of ATG-containing conditioning, and in-
fused cell numbers, there was no significant difference
in immune recovery between the WM-UDT and
FMT groups.
GVHD and CMV Infection
The cumulative incidence of aGVHD grade II or
greater was 48.5% (95% confidence interval [CI],
30.4%-64.4%) after WM-UDT, 38.5% (95% CI,
13.0%-63.9%) after PM-UDT, and 52.2% (95% CI,
29.7%-70.5%) after FMT (Figure 3A). The corre-
sponding values for cGVHD were 51.9% (95% CI,
32.0%-68.6%), 38.5% (95% CI, 12.5%-64.5%), and
47.8% (95% CI, 26.1%-66.7%) (Figure 3B). There
were no significant differences in the cumulative inci-
dence of either aGVHD (P 5 .653) or cGVHD
(P 5 .256) among the donor groups. Among all pa-
tients with aGVHD (n 5 39), only 6 patients devel-
oped grade III-IV aGVHD; the proportion did noteutrophil engraftment. (B) Platelet engraftment.
Figure 2. Posttransplantation immune reconstitution measured by lymphocyte subsets: CD561 cells (A) CD41 cells (B) CD81 cells (C) and CD191
cells (D).
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WM-UDT versus 17% for PM-UDT versus 23%
for FMT; P 5 .617). Similarly, the proportion of
severe cGVHD did not differ significantly among
the groups (38% for WM-UDT versus 20% for
PM-UDT versus 40% for FMT; P 5 .137).Figure 3. Cumulative incidences of major complications after transplant
DNAemia (C).Fifty-one of the 69 patients (73.9%) had at least 1
positive CMVDNAPCR assay result at amedian of 30
days (range, 11-71 days) after SCT, and 34 patients
(49.3%) required preemptive treatment with ganciclo-
vir or foscarnet. Seven of these patients developed
CMV disease, including CMV enterocolitis (colon,ation according to donor type: aGVHD (A) cGVHD (B) and CMV
1558 Biol Blood Marrow Transplant 18:1552-1563, 2012B.-S. Cho et al.n5 5; duodenum, n5 1; stomach, n5 1), CMV pneu-
monia (n 5 1), CMV encephalitis (n 5 1), or retinitis
(n 5 1), and uncontrolled CMV disease was a cause
of death in 3 patients. The cumulative incidence of
CMV DNAemia was 66.7% (95% CI, 47.3%-
80.3%) after WM-UDT, 63.1% (95% CI, 28.3%-
84.5%) after PM-UDT, and 91.3% (95% CI,
64.0%-98.2%) after FMT (Figure 3C). The inci-
dences did not differ significantly among the 3 groups
(P 5 .124), but a comparison between the combined
unrelated donor groups (WM-UD and PM-UD;
n 5 46) and FMT showed a higher incidence of
CMV DNAemia in the FMT group (P5 .047). How-
ever, the proportion of CMV diseases did not differ
significantly among the donor groups (6.1% for
WM-UDT versus 7.7% for PM-UDT versus 17.4%
for FMT, P 5 .390; 6.5% for the combined unrelated
donor groups versus 17.4% for FMT, P 5 .211).
Survival Outcomes
At a median follow-up of 28 months (range, 9-37
months) for surviving SCT recipients, the 3-year OS
was 83.3% (95% CI, 70.9%-97.9%) after WM-UDT
versus 51.3% (95% CI, 29.3%-89.7%) after PM-
UDT versus 65.7% (95% CI, 47.4%-90.9%) after
FMT (P 5 .161), and corresponding 3-year DFS was
73.7% (95% CI, 59.5%-91.3%) versus 51.3% (95%
CI, 29.3%-89.7%) versus 63.8% (95% CI, 46.3%-
87.8%) (P 5 .410) (Figure 4A and B). The 3-year cu-
mulative incidence of relapse was 19.5% (95% CI,
7.7%-35.2%) after WM-UDT versus 30.8% (95%
CI, 8.7%-56.6%) after PM-UDT versus 26.1%
(95% CI, 10.3%-45.2%) after FMT (P 5 .679), and
that of NRM was 6.8% (95% CI, 1.1%-19.9%) after
WM-UDT versus 17.9% (95%CI, 2.2%-46.1%) after
PM-UDT versus 10.1% (95% CI, 1.5%-28.1%) after
FMT (P 5 .845) (Figure 4C and D). Among all pa-
tients, causes of NRM included cGVHD with severe
sepsis (n 5 2) for WM-UDT, steroid-refractory
aGVHD combined with CMV enterocolitis (n 5 1)
and cGVHD with severe sepsis (n 5 1) for PM-
UDT, and steroid-refractory aGVHD combined
with multiorgan CMV diseases (n 5 1; colon, lung,
eye, and brain) and veno-occlusive disease with CMV
enterocolitis (n 5 1) for FMT.
Factors Affecting Major Outcomes after SCT
Table 3 presents factors affecting major outcomes
after SCT. Univariate analyses found a lower OS for
the PM-UDT group compared with the WM-UDT
group but no difference in OS between the FMT and
WM-UDT groups. The cumulative incidences of re-
lapse and cGVHD did not differ according to the do-
nor type, whereas the FMT group showed a trend for
a higher rate of CMV DNAemia compared with the
WM-UDT group. Patients with a WBC count ex-ceeding 50  109/L at diagnosis had lower OS and
a higher trend for relapse. TBI-containing condition-
ing regimens and older age were associated with the
risk of cGVHD and CMV DNAemia, respectively.
No relevant factors associated with DFS, NRM, or
grade II-IV aGVHD were identified in this cohort.
Multivariate analyses revealed significantly lower
OS in the PM-UDT group compared with the
WM-UDT group but no significant difference in
other survival outcomes, including DFS. There were
no significant differences in any of the survival out-
comes between WM-UDT and FMT groups. WBC
count at diagnosis also remained significant. Relapse
rate was significantly higher in patients with a WBC
count.50  109/L at diagnosis. TBI-containing con-
ditioning regimen and older age were significantly as-
sociated with cGVHD and CMV DNAemia,
respectively, whereas there was no significant differ-
ence according to the donor type except for a trend to-
ward increased risk of CMV DNAemia in the FMT
group compared with the WM-UDT group. This
trend became apparent in a comparison with the com-
bined unrelated donor groups (WM-UD and PM-
UD; n 5 46), with a significantly higher incidence of
CMV DNAemia in FMT (hazard ratio, 1.83; 95%
CI, 1.04-3.23; P 5 .036).DISCUSSION
The recently reported encouraging outcomes of
FMT with MAC with or without ex vivo T cell deple-
tion [15-18] or RIC without ex vivo T cell depletion
[32-36] have made FMT a feasible option for SCT in
patients without a suitable donor. In particular, FMT
has merit as an alternative graft source in patients
with AML, given the superior survival outcomes in
patients with donor NK cell alloreactivity
demonstrated in a study that included only patients
with AML [16], although conflicting data have been
reported [19]. However, most previous studies in-
cluded patients with other hematologic malignancies
besides AML, making it difficult to estimate the role
of FMT in each disease [15,17,18,32-36]. Thus, at
least for patients AML, the pros and cons of FMT
compared with SCT with other donor types should
be evaluated. In the present study of patients with
high-risk AML, which compared outcomes of FMT
using novel conditioning regimens with SCT from un-
related donors in the absence of an HLA-matched sib-
ling, we have confirmed the feasibility of FMT using
our novel regimen, particularly in terms of prompt en-
graftment with no graft failure and a lower NRM. The
rates of engraftment and immune reconstitution or the
cumulative incidences of aGVHD and cGVHD did
not differ significantly according to donor type, al-
though the rate of CMV DNAemia was higher in the
FMT group compared with the other 2 groups.
Figure 4. Survival outcomes according to donor type: OS (A) DFS (B) relapse (C) and NRM (D).
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ing, infusion of T cell–replete bone marrow grafts,
and GVHD prophylaxis with MTX, with or without
cyclosporine. These strategies were complicated by ex-
cessive bidirectional alloreactivity, resulting in high
rates of graft failure, severe GVHD, and NRM
[12,13]. The recent advances in FMT were
stimulated by investigators in Perugia, Italy, who
achieved low rates of graft failure (7%-8%) and
aGVHD (8%-25%) with MAC (TBI 800 cGy/
thiotepa/fludarabine/ATG) with rigorously ex vivo T
cell–depleted PBSCs containing megadoses of
CD341 cells and no further GVHD prophylaxis in
patients with acute leukemia [15,16]. Survey data in
Europe also found that FMT using MAC with
ex vivo T cell–depleted PBSCs can be an alternative
treatment option in high-risk patients with acute leu-
kemia in remission who lack an HLA-matched donor.
However, the 29%-48% DFS in FMT using MACwith graft manipulation is somewhat disappointing,
even in remission, due to the high NRM (32%-45%)
caused by infection-related mortality associated
with poor posttransplantation immune reconstitution
[15-17]. Peking University researchers reported
outcomes of FMT in acute leukemia using a novel
approach with MAC (cytosine arabinoside/busulfan/
cyclophosphamide/simustine/ATG) without ex vivo
T cell depletion, including GVHD prophylaxis with
a calcineurin inhibitor, MTX, and mycophenolate
mofetil [18]. Three-year DFS, NRM, and relapse in
patients with remission at transplantation were 71%,
19%, and 11%, respectively, without graft failure, in
contrast to 7%-8% of graft failure of the aforemen-
tioned approach using MAC with rigorous ex vivo
T cell depletion [15,16]. Recently, the same group
reported that survival outcomes in FMT were
comparable to those of transplantations from
unrelated donors in a variety of hematologic diseases,
Table 3. Potential Factors at Transplantation Affecting Transplantation Outcomes
n
Overall Survival Relapse cGVHD CMV Infection
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Univariate variables
Donor type
WM-UDT 33 1 1 1 1
PM-UDT 13 3.61 (1.10-11.84) .034 2.16 (0.61-7.65) .235 0.82 (0.30-2.26) .703 0.87 (0.39-1.96) .735
FMT 23 2.33 (0.74-7.38) .149 1.65 (0.53-5.13) .386 1.77 (0.83-3.78) .143 1.70 (0.93-3.10) .085
WBC at diagnosis,  109/L
<50 57 1 1 - -
$50 11 2.69 (1.01-7.19) .048 2.60 (0.90-7.50) .077 - -
Conditioning regimen
TBI 56 - - 1 -
Non-TBI 13 - - 0.18 (0.04-0.74) .017 -
Age of patient 69 - - - 1.02 (1.00-1.04) .046
Multivariate variables
Donor type
WM-UDT 33 1 1 1 1
PM-UDT 13 4.47 (1.33-15.0) .016 2.64 (0.72-9.70) .143 0.62 (0.22-1.74) .369 0.95 (0.42-2.16) .909
FMT 23 2.77 (0.87-8.88) .102 1.90 (0.60-5.98) .274 1.19 (0.55-2.57) .664 1.84 (1.00-3.38) .051
WBC at diagnosis,  109/L
<50 57 1 1 - -
$50 11 4.19 (1.45-12.06) .001 3.09 (1.04-9.16) .042 - -
Conditioning regimen
TBI 56 - - 1 -
Non-TBI 13 - - 0.18 (0.04-0.77) .021 -
Age of patient 69 - - - 1.03 (1.01-1.05) .034
HR indicates hazard ratio.
No relevant factors were associated with DFS, NRM, or aGVHD grade II-IV on univariate analyses.
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information about the difference in outcomes
between FMT and WM-UDT or PM-UDT with re-
spect to the degree of HLA mismatch [37]. Several
clinical trials also have shown the feasibility of RIC
for FMT in adult patients with a variety of hemato-
logic diseases, a majority of whom used unmanipulated
PBSCs with intensive GVHD prophylaxis, including
pretransplantation ATG or alemtuzumab, or high-
dose posttransplantation cyclophosphamide, as well
as a calcineurin inhibitor with or without MTX or my-
cophenolate mofetil [32-36]. Compared with the
aforementioned outcomes in FMT using MAC,
similar rates of DFS (35%-55%) and aGVHD (16%-
31%) with lower NRM (15%-31%) have been
observed after FMT using RIC at a cost of relatively
higher rates of engraftment failure (4%-16%) and
relapses (27%-58%) [32-36], even though the direct
comparison is difficult because the majority of trials
for FMT using RIC included a variety of diseases
and different proportion of advanced disease status at
transplantation. Regardless of conditioning intensity,
previous studies have shown poor survival outcomes
for FMT in patients with advanced disease status at
the time of transplantation [15-18,32-36]. Taken
together, these data indicate that FMT after both
MAC and RIC is a feasible option for patients
lacking a suitable HLA-matched donor, particularly
those not in an advanced disease status at the time of
transplantation. However, who will receive the bestbenefit from MAC and RIC or the order of priority
among alternative graft sources, especially in
a homogeneous disease population, remains to be
determined.
We reported our previous experience of FMT us-
ing MAC with ex vivo T cell depletion in patients with
high-risk AML without further GVHD prophylaxis,
the majority of whom were in advanced disease status
at transplantation (CR1, n 5 2; CR2, n 5 1; CR3,
n 5 1; refractory, n 5 4) [38]. The conditioning regi-
mens differed from the current FMT regimen with re-
spect to doses of TBI (1200 cGy versus 800 cGy) as
well as busulfan (3.2 mg/kg/day for 3 days versus for
2 days) and fludarabine (40 mg/m2/day for 4-5 days
versus 30 mg/m2/day for 5 days). All patients promptly
engrafted, but other clinical outcomes were disap-
pointing. Six of the 8 patients died from relapse
(n 5 2) or infection-related complications (n 5 4),
and only 2 patients with CR1 at the time of transplan-
tation were alive. In contrast, the present study found
a remarkable improvement in survival outcomes in pa-
tients undergoing FMT for high-risk AML, especially
decreased NRM, after reducing the conditioning in-
tensity and using T cell–replete PBSCs with GVHD
prophylaxis. Recent studies using RIC regimens for
FMT without ex vivo T cell depletion also achieved
success in reducing NRM by decreasing infection-
related mortality and showed prompt immune recov-
ery after FMT [32-36], whereas prolonged immune
suppression, delayed immune reconstitution, and the
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patients who underwent FMT with ex vivo T cell
depletion [15-17]. Of note, the prompt engraftment
without any graft failure in this pilot study contrasts
with recent data for FMT using RIC showing 4%-
16% engraftment failure despite successful survival
outcomes [32-36]. Our RIC regimen uniquely
includes TBI 800 cGy compared with other reported
RIC-FMT regimens, which may contribute to
a more successful engraftment, even though the direct
comparison is difficult, given the different kinds of
diseases and varying disease status at transplantation
[32-36].
In the present study, survival outcomes for patients
undergoing FMT were comparable to those undergo-
ingWM-UDT, which is considered the gold standard
donor transplantation when a matched sibling is un-
available. Despite the statistical insignificance, the dif-
ference in OS between the WM-UDT and FMT
groups (83% versus 66%) may be considered quite
substantial. However, the difference in DFS between
the 2 groups (74% versus 64%) was smaller than that
in OS because more patients in the WM-UDT group
survived in relapsed status at the date of last follow-up.
Considering that eventual death may occur in patients
with relapsed leukemia, DFS is a more reliable end-
point than OS for evaluating survival outcomes in pa-
tients with AML. Thus, the smaller difference of DFS
compared withOSmay support comparable survival in
the WM-UDT and FMT groups in this pilot study.
Disease status at time of transplantation, one of the
most important prognostic factors, was similar for
the 3 donor groups, justifying the comparable out-
comes of FMT. However, the post hoc power calcula-
tions for DFS between the WM-UDT and FMT
groups ranged from approximately 15% to 44%, sug-
gesting that the clinically relevant differences among
donor groups might not be detectable because of the
small sample sizes. Thus, further well-controlled stud-
ies of larger numbers of patients are needed to address
this issue. In addition, the relatively higher proportion
of patients with CR1 at time of transplantation (75%)
in the present study compared with previous studies of
FMT, including variable proportions of patients in
CR1 at transplantation but\50% (14%-45%) in acute
leukemia, might have contributed to the relatively
higher survival rate in our FMT group [15-18,32-
36,38], suggesting the benefit of FMT in patients
with favorable disease status at the time of
transplantation.
In our center, PM-UD has been used as an alterna-
tive donor source, whereas mismatched unrelated do-
nors with 2 or more allele mismatches have hardly
been used since 2008 because of their poor outcomes,
as reported by the Center for International Blood and
Marrow Transplant Research [9,10]. However, few
studies have compared clinical outcomes of SCTwith PM-UDwith those of SCTwith standard donors,
such as an HLA-matched sibling or a WM-UD, in
AML as a single disease. A multicenter prospective
study fromGermany reported that donor type, includ-
ing HLA-matched sibling, WM-UD, PM-UD, and
mismatched unrelated donors, was not a major prog-
nostic factor in elderly persons with AML [39]. On
the other hand, recent Center for International Blood
andMarrowTransplant Research data showed inferior
survival of PM-UDT compared with HLA-matched
sibling SCT in patients with AML in CR1 with unfa-
vorable cytogenetics, in contrast to the similar out-
comes seen in WM-UD and HLA-matched sibling
SCT [40]. The present study also found a trend for in-
ferior survival outcomes in PM-UDT compared with
FMT orWM-UDT, but the small number of patients
in each donor group makes it difficult to draw a defin-
itive conclusion. Thus, further studies comparing
donor types with a large number of patients, particu-
larly patients with AML in remission, are needed to
clarify the role of PM-UD in AML. In this context,
the trend for favorable survival of FMT over PM-
UDT needs to be validated with prospective studies
comparing FMD directly with other alternative donor
types. The effect of donor NK cell alloreactivity,
shown to be associated with a decrease in relapse of
AML after ex vivo T cell–depleted FMT [16], should
also be evaluated in the setting of SCT from mis-
matched donors with T cell–replete grafts, although
we did not find such an effect in FMT and PM-
UDT in the present study.
In addition to survival outcomes, FMT had both
a similar pattern of immune reconstitution and compa-
rable incidences and severity of aGVHD and cGVHD
as SCT from unrelated donors. The comparable inci-
dence of aGVHD in FMT even with T cell–replete
grafts is another intriguing finding of this study, given
that the high rate of aGVHD and NRM led to the de-
velopment of ex vivo T cell–depleted FMT [15-17].
Only 9% of our patients (6 of 69) developed severe
aGVHD (grade III-IV), with a similar proportion
among the 3 donor groups, which contributed to
a low NRM. A possible explanation for the lower inci-
dence of aGVHD in FMT is that Korean patients are
an ethnic population with a low level of HLA gene het-
erogeneity [41], as supported by consistent data from
another Korean study of FMT using RIC with
T cell–replete grafts demonstrating lower rates of
GVHD [36]. On the other hand, the present study
shows a higher incidence of CMV DNAemia in the
FMT group compared with the 2 unrelated donor
groups, possibly related to the higher ATG doses
used in the FMT group. Our strategy of reinforcing
CMV prophylaxis with ganciclovir instead of high-
dose acyclovir during the conditioning period for
FMTwas not effective in preventing CMVDNAemia;
however, the prevalence of CMV diseases was not
1562 Biol Blood Marrow Transplant 18:1552-1563, 2012B.-S. Cho et al.significantly different among our 3 donor groups, pos-
sibly related to the preemptive treatment based on
PCR monitoring. Nevertheless, for FMT, novel ap-
proaches such as immunotherapy and drug prophylaxis
should be considered in the future, given the high risk
for CMV DNAemia in the Korean population, with
CMV seropositivity detected in all but 1 patient in
our cohort.
Our data need to interpreted with caution, for sev-
eral reasons. First, the small number of patients in each
donor group limited our statistical power calculations.
The 3 donor groups might not be truly equivalent in
terms of patient- and disease-related factors, because
the patients were not randomized, although no statis-
tically significant differences were seen among the do-
nor groups. In addition, there may be other important
factors that we have not been able to take into account.
Finally, the ethnically homogeneous study population
might limit the generalizability of our conclusions to
other more diverse populations. Thus, well-designed
prospective studies to address the issues raised by the
current study are needed.
In summary, this study has shown the feasibility of
FMT using our novel RIC regimen without ex vivo
T cell depletion compared with concurrently per-
formed WM-UDT and PM-UDT. The prompt en-
graftment with no increase in risk of severe GVHD
and favorable survival outcomes are advantages of our
FMT regimen, but the increased risk of CMV
DNAemia suggests the need for more aggressive
CMV prophylaxis. Further well-controlled trials with
a large number of patients, comparing FMT directly
with other donor types, are needed, given the aforemen-
tioned limitations of this study. In addition, studies
comparing outcomes in patients who underwent FMT
and a case-matched cohort of patients with AML who
did not undergo allogeneic SCT, focusing on patients
with CR1, are needed to clarify the role of FMT.ACKNOWLEDGMENTS
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